CoChat

Misuse of the γ‐aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK

Open access
Kapil, Vikas, Green, Jody L., Le Lait, Marie‐Claire, Wood, David M., Dargan, Paul I. · 2014 · British Journal of Clinical Pharmacology
Cited by 98

The DOI matches its Crossref record.

Abstract

γ-Aminobutyric acid (GABA)-analogue medications, including gabapentin and pregabalin, are recommended first-line treatments for neuropathic pain in the UK 1, and pregabalin has been used in the treatment of various psychiatric conditions, including generalized and social anxiety disorders 2. Consequently, there has been a large increase in prescription of these drugs over the last decade 3. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) recently highlighted early reports from pharmacovigilance data from four countries, including the UK, regarding the potential for misuse of these medications and indications from toxicological analyses of the involvement of these medications in deaths of users 4. There is also concern regarding their access from online pharmacies and misuse of legitimately prescribed medication 5. Furthermore, dependent users of recreational drugs may seek access to these medications in an attempt to prevent or treat withdrawal symptoms 3, 6, 7. However, to date there have been no data reported on the prevalence of the misuse of these medications in any country. The aim of this study was to determine the prevalence, frequency and sources of misuse of the GABA analogues (baclofen, gabapentin and pregabalin) in the UK. We partnered with a global market research company, GMI (http://www.gmi-mr.com/global-panel), which has an established global consumer panel of millions of persons. We devised a question-based survey that was formulated by the company into an Internet-based survey (see Appendix S1). Invitations were sent by GMI to existing market research panel members in the UK only, between the ages of 16 and 59 years, and respondents were capped at a maximum of 1500. The raw data of the responses to the questions were given to us, linked to a fully anonymized unique personal identifier. Basic demographics were collected together with data on lifetime prevalence and frequency of misuse of baclofen, gabapentin and pregabalin; where individuals had misused one of these drugs, they were asked to indicate the source(s) of supply for misuse. We included questions based on lifetime prevalence of use of recreational drugs [cocaine, cannabis and 3,4-methylenedioxy-N-methylamphetamine (MDMA, 'ecstasy')] so that we could benchmark against existing national data provided by the 2011/2012 Crime Survey for England and Wales 8. In this way, we could confirm that our survey population provided a reasonable sample of the national population in the UK with respect to recreational drug use and therefore medications misuse. The online survey was completed by 1500 individuals [male, 49.1% (n = 737) and female, 50.9% (n = 763)]; 9.1, 40.5, 21.1 and 29.3% were aged 16–20, 21–39, 40–49 and 50–59 years old, respectively. Lifetime prevalence of use of recreational drugs was comparable to national data from the 2011/2012 Crime Survey for England and Wales. Within the survey cohort, self-reported lifetime prevalence of use of cocaine was 8.1%, cannabis 28.1% and MDMA 8.2%; compared with 9.5, 31.0 and 8.6%, respectively, for the three recreational drugs in the 2011/2012 Crime Survey for England and Wales 7. The lifetime prevalence of misuse of any of the three surveyed GABA-analogue medications was 2.5% (n = 38); for each drug, this was 1.3% (n = 19) for baclofen, 1.1% (n = 17) for gabapentin, and 0.5% (n = 8) for pregabalin. The frequency of misuse was less than once monthly in 36.8% (n = 14), between once monthly and once weekly in 50% (n = 19), and more than once weekly in 13.1% (n = 5). Of the people misusing these medications, 36.8% (n = 14) obtained their supply from multiple sources, with similar rates of sourcing overall from health services (63.1%, n = 24), from family or acquaintances (57.8%, n = 22) and from the Internet (47.3%, n = 18), with only 7.8% (n = 3) obtaining the medication from abroad. Misuse of medication that had been legitimately prescribed to the individual was the sole source for only 13.1% (n = 5). This study, to our knowledge, is the first report to estimate the prevalence of misuse of GABA-analogue medications conducted in a cohort with similar lifetime prevalence of use of recreational drugs to the UK population. Whilst we did not confirm substance misuse by structured interview or specific analysis, our results suggest that there is appreciable misuse of baclofen, gabapentin and pregabalin in the UK, with approximately one in 40 of survey respondents self-reporting misuse of any of the GABA-analogue medications. The provenance of the majority of misuse appears to be from sources other than legitimately prescribed medication, which has important implications for future strategies to reduce access to these medications. Similar surveys can be used to determine the robustness of early pharmacovigilance data, such as that provided by the EMCDDA, to help regulatory and law-enforcement agencies understand the epidemiology of substance misuse and decide whether further contr

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bcp.12277

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 98

Metadata

Authors
Kapil, V., Green, J. L., Le Lait, M., Wood, D. M., & Dargan, P. I.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2014-06-20
Volume
78
Issue
1
Pages
190-191
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1908826089
Cited by
98
References
0
FWCI
5.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Misuse of the γ‐aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. https://app.cochat.ai/papers/10.1111/bcp.12277
The paper
Kapil, V., Green, J. L., Le Lait, M., Wood, D. M., & Dargan, P. I. (2014). Misuse of the γ‐aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.12277

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.